Preclinical studies have been limited by the use of xenograft models that do not adequately recapitulate the immune system of a clinically relevant host, so we developed the Nectin4 mCAR-T cells to determine its anti-tumor effects in a fully immune-competent mouse model of metastatic colorectal cancer. This evidence concerns the gene NECTIN4 and neoplasm.